A recent review study conducted by Kubota et al. [17] concluded that the SGLT2 inhibitors exhibit antidiabetic effects and play a crucial role in reducing cardiovascular events in patients with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.